Evercore ISI downgraded Avidity Biosciences (RNA) to In Line from Outperform with a price target of $72, up from $65. Novartis (NVS) has agreed to acquire Avidity for $72 per share in cash and the acquisition is expected to close in the first half of 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity reports FTC granted request for early termination of HSR waiting period
- Avidity Biosciences Receives FTC Clearance for Novartis Merger
- Hold Rating on Avidity Biosciences Amid Novartis Acquisition and Strategic Developments
- Hold Rating on Avidity Biosciences Amid Novartis Acquisition Uncertainty
- Avidity Biosciences Reports Increased Revenue Amid Losses